Glial cell linederived neurotrophic factor protect Parkinson model rat substantia nigra dopaminergi.docx
- 文档编号:12447209
- 上传时间:2023-04-19
- 格式:DOCX
- 页数:10
- 大小:21.38KB
Glial cell linederived neurotrophic factor protect Parkinson model rat substantia nigra dopaminergi.docx
《Glial cell linederived neurotrophic factor protect Parkinson model rat substantia nigra dopaminergi.docx》由会员分享,可在线阅读,更多相关《Glial cell linederived neurotrophic factor protect Parkinson model rat substantia nigra dopaminergi.docx(10页珍藏版)》请在冰豆网上搜索。
GlialcelllinederivedneurotrophicfactorprotectParkinsonmodelratsubstantianigradopaminergi
Glialcellline-derivedneurotrophicfactorprotectParkinsonmodelratsubstantianigradopaminergicneuronsmechanismanalysis
Author:
DingYanxia,LIUHong-Mei,WangHongjun,WangYanjiang,highDianshuai
[Keywords]dopaminergicneuronsAbstract:
ObjectiveTostudytheglialcellline-derivedneurotrophicfactor(glialcellline-derivedneurotrophicfactor,GDNFprotectdopaminergic(dopamine,DAneuronsprocess,thecalcium-bindingproteinD28K(calbindin28K,CBandastrocytesthepossibleroleofinterstitialcells.Methodsrightstriatumofratsinjectionof6-hydroxydopamine(6-OHDA)PreparationofParkinson’sdisease(Parkinsondisease,PDmodelinjectionafterthe7thday,basedonbehavioranalysisscreeningmodelmouse,modelmicewererandomlydividedintothreegroups:
controlgroup,PBSgroup(therightsideofthesubstantianigrainjectionofPBSandGDNFgroup(rightsubstantianigrainjectionsofGDNFtheblankcontrolanimals,respectively,in6-OHDAinjectionafter7days,14dayssubstantianigra,21daysand28days,thePBSgroupandGDNFgroupanimalsinthefirst14daysafterthe6-OHDAinjection,respectively,21and28days,linesegmentscontinuouscoronalparaffin,tyrosinehydroxylase(tyrosinehydroxylase,TH,CBandglialfibrillaryacidicprotein(glialfibrousacidproteinofGFAPimmunohistochemistrystaining,respectivelyDAneurons,includingtheCBneuronsandastrocytes,lightmicroscopyandcellcount,statisticallyprocessingresults①THimmunohistochemicalstainingresults:
6-OHDAinjectionafter28days,theexpressionoftherightsideoftheGDNFgroupratsubstantianigraTHpositiveneuronswassignificantlymorethanthecontrolgroupandPBSgroup;②CBimmunohistochemicalstainingresults:
CBpositiveneuronssevendaysafterinjectionof6-OHDA,therightsideoftheblankcontrolgroupratssubstantianigracanstillbeobserved,afterthepointintimeofthecontrolgroupandthePBSgrouparenotobserved,therightbooksandGDNFratseachtimepointthesubstantianigrainthedetectionofCBpositiveneurons;3ofGFAPimmunohistochemistryresults:
blankcontrolgrouponthe7thdayaftertheinjectionof6-OHDAsmallamountofGFAPpositivecellscouldbeobservedafterinjection14daysexpressionofGFAPpositivecellsreachedapeak,andthengraduallyreduceto28daysaftertheinjectionhasbeenbasicallyundetectable;thePBSgroupGFAPexpressionconsistentperformanceofthenumberofpositivecellsintheblankcontrolgroup,andthetheGDNFgroupratsubstantianigraintheThedetectionofthepointintimecanbeobservedinalargenumberofreactivehyperplasiaofastrocytesconclusionCBand(orastrocytesmaybeinvolvedinGDNFtoprotectandpromotethesurvivalofPDmodelratsubstantianigraDAneurons.
Keywords:
dopaminergicneurons;glialcellline-derivedneurotrophicfactor;astrocytes;calcium-bindingproteinD28KAbstract:
ObjectiveToexplorethepossiblerolesofastrocytesandcalbindinD28K(CBintheprocessforglialcellline-derivedneurotrophicfactor(GDNFtoprotectdopaminergicneurons(DAneuronsinratsubstantianigra(SNagainst6-hydroxydopamine(6-OHDA)neurotoxicity.MethodsRatmodelofParkinsondisease(PD)wasestablishedbyster-eotaxicalinjectionof6-OHDAintotherightstriatum,withthequalifiedmodelsscreenedbypassingthebehavioraltests.Themodelratswererandomlydividedintothreegroups:
PDcontrol,PBStreatmentcontrolandGDNFtreatmentgroups,toundergovariedtreatments.Theanimalsweredecapitated1-4weeksafter6-OHDAinjectiontoproceedwiththehistologicstudyonthecontinuouscoronalsectionsoftheratmidbrainbymeansofimmunohistochemistryusingthaantibodiesagainsttyrosinehydroxy-lase(TH,CBandglialfibrillaryacidicprotein(GFAPtodetecttheDAneurons,CB-containingneuronsandastrocytesre-spectively.Results(1ThedensityofTHpositivecellswassignificantlyhigherintheGDNFtreatmentgroupthanthatinthecontrolgroups.(2TheCBpositiveneuronscouldonlybeseenonthe7thdayafter6-OHDAinjectioninthecontrolgroups,buttheypersistedintheGDNFtreatmentgroupthroughthewhole28-daycourseofexperiment.(3Inthetwocontrolgroups,theGFAPpositivecellsemergedonthe7thdayafter6-OHDAinjection,reachedtheclimaxstaininganddesityonthe14thday,begantodeclineonthe21thdayandalmostdisapearedonthe28thday.However,intheGDNFtreatmentgroup,thephe-nomenonofactivationofastrocytescouldbeevidencedthroughouttheexperimentalcourse.ConclusionCBand.orastrocytesmaybeinvolvedinthemechanismforGDNFtoprotectDAneuronsagainst6-OHDAneurotoxicity.
Keywords:
:
dopaminergicneuron;glialcellline-derivedneurotrophicfactor;astrocyte;calbindinD28k
Parkinson’sdisease(Parkinson,disease,PDcharacteristicpathologicalchangesindopaminergic(ofdopamineinthebrain,progressivedegenerationofDAneuronsdeath.Neuroprotectivetherapyiscommittedtoblockordelaytheprocessofneuronaldegenerationpromotetheremnantsofneuronsrestorationandrepair.retrospectiveanalysisofthebrainofPDpatientsshowconsiderablenumberofDAneuronsisstillinthesurvivalstatus[1],whichprovidesatheoreticalbasisfortheneuroprotectivetreatmentatthesubstantianigra.glialcellline-derivedneurotrophicfactor(glialcellline-derivedneurotrophicfactor,GD-NFsofaridentifiedinthemidbrainDAcanneuronsneurotrophicrolestrongestfactoroneofalargenumberofstudieshaveshownthat,GDNFcanpreventorreversePDprogressivedegenerationofthenigrostriatalDAsysteminanimalmodels[2],neuroprotectivetherapyforPDpreferredneurotrophicfactor.,however,thebodyGDNFishowtoprotectandpromotetheDAneuronssurvivedsofartostudyverylesscalcium-bindingproteinD28K(calbindinD28K,CBisacalcium-bindingproteinfamilymembers,canbecombinedwithcalciumionswithinthecell,thecellsfromthetoxiceffectsofhighcalciumproduced,thuscytoprotective3]Inthisstudy,usingimmunohistochemicalstaining,detectionofGDNFintheprotectionofDAneuronsprocess,CBandastrocytemarkerglialfibrillaryacidicprotein(glialfibrillaryadietwhichprotein,GFAPexpression,substantianigraDAexploreGDNFprotectionofneuronsprocess,theCBandthepossibleroleofastrocytes,soastofurtherexploretheGDNFprotectionmechanismofDAneuronsprovideatheoreticalbasis.
1Materialsandmethods
1.1AnimalsandreagentshealthyadultmaleSprague-Dawley(SDrats,weighing200to250g,providedbytheExperimentalAnimalCenterofXuzhouMedicalCollege.RecombinanthumanofGDNF,6-hydroxydopamine(6-hydroxydopamine,6-OHDA,miceKangDatheratTHmonoclonalantibody,mouseanti-ratCBmonoclonalantibody,rabbitanti-ratGFAPmonoclonalantibodyandABCkit(SigmaChemicalCo.;stereotaxicinstrument(Kopf,Japan;closedwithgoatserumstocksolution(BeijingZhongshan.
1.2stereotaxicinjectionintraperitonealinjectionofsodiumpentobarbital(50mg.kganesthesia,anesthesiaago,5~10minintraperitonealinjectionofatropine(breathinganimal0.1mg.kgtofacilitatesurgery.AccordingtoPaxinosandWatson(1986)Spectrumselectcoordinaterightstriatuminratsinjectionof6-OHDA:
6-OHDAsolutionwasformulatedinsterilesaline(containing0.02%ofascorbicacid,thefinalconcentrationof3g.Lof4μl.coordinates(mm:
P(anteriorfontanelle+1.6;L(nexttoopen1.5;V(subdural4.8and5.6.7daysafterinjection,basedonbehavioralsciencedetectionscreening50PDmodelratswererandomlydividedintothreegroups:
blankcontrolgroup(n=20,theexperimentalcontrolgroup(ipsilateralsubstantianigraattherightsideofthesubstantianigrainstereotacticinjection:
ofGDNFsolutiontosterileinjectionofPBS,n=15,andtheexperimentalgroup(ipsilateralsubstantianigrainjectionsofGDNF,n=15.the0.01mol.LPBSpreparation,itsfinalconcentration5mg.L,of2μl,experimentalcontrolgroupinjectedwiththesamevolumeofsterile0.01mol.LPBS.coordinates(mm:
P,-4.9;L,and1.8;V8.1with5μltheHamitonmicroinjectorextractliquidinjectionspeed0.5μl.min,Notecompletionoftheneedlefor5minand1mm.minspeedslowexit.
1.3Behaviordetection
1.3.1postureasymmetryChiangdescribedin[4],filedtherat-tailedratswerevacantintheexperimentalstagesideabout10cmtoobserveratheadorbodyrotationdirection,doit20times,whichisrotatedtotheleftTheshareoffrequencyastheevaluationindex.
1.3.2forelimbinitiationcannotbebasedonOlssonetal[5],andLind-neretal[6]describedthesecondhalfoftheratbodyholdup,andbodyweightinratsonlysupportedbythesideoftheforelimbs,record10swithinratforelimbwalkingtimes,andthenusethesamemethodstomeasuretheothersideoftheforelimbrightlimbasymmetryscoreastheevaluationindex,calculatedasfollows:
(numberofstepsontheright-thenumberofstepsontheleftbothsidesofthetotalnumberofsteps.
1.4drawnslicedblankcontrolanimalsafterthe6-OHDAinjection,respectivelyfirst7days,14days,21daysand28days,PBSgroupandGD-NFgroupsofanimals,respectively,14daysafterthe6-OHDAinjection,21daysand28day(eachtimepointn=5,4%anesthetizedbyintraperitonealinjectionofsodiumpentobarbital,ascendingaorticcannulationthroughtheleftventricle,4%paraformaldehydefixedtothebackoftheheadfixedinthesamefixativefor24hours.conventionalThedehydration,transparent,waxdippedandembedding.substantianigrasegmentcontinuouscoronalslices,slicethickness6μm,slicingpacketcollection.
1.5Immunohistochemicalstainin
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Glial cell linederived neurotrophic factor protect Parkinson model rat substantia nigra dopaminergi
链接地址:https://www.bdocx.com/doc/12447209.html